吉林大学学报(医学版) ›› 2016, Vol. 42 ›› Issue (01): 48-53.doi: 10.13481/j.1671-587x.20160110

• 基础研究 • 上一篇    下一篇

黄芪甲苷对糖尿病肾脏病变大鼠氧自由基代谢和转化生长因子β1mRNA表达的影响

黄晓东1, 沈楠2, 路倩1, 刘微1, 常影1, 范红艳1, 王艳春1   

  1. 1. 吉林医药学院药理学教研室, 吉林吉林 132013;
    2. 吉林医药学院机能实验中心, 吉林吉林 132013
  • 收稿日期:2015-06-03 发布日期:2016-01-26
  • 通讯作者: 王艳春,教授,硕士研究生导师(Tel:0432-64560470,E-mail:wangyanchun1972@163.com) E-mail:wangyanchun1972@163.com
  • 作者简介:黄晓东(1978-),男,辽宁省抚顺市人,讲师,医学博士,主要从事药理学方面的研究。
  • 基金资助:

    吉林省科技厅科研基金资助课题(201105088);吉林省教育厅"十二五"科学技术研究项目资助课题(2014547)

Effect of astragaloside on oxygen radical metabolism and expression of TGF-β1 mRNA in diabetic nephropathic rats

HUANG Xiaodong1, SHEN Nan2, LU Qian1, LIU Wei1, CHANG Ying1, FAN Hongyan1, WANG Yanchun1   

  1. 1. Department of Pharmacology, Jilin Medical College, Jilin 132013, China;
    2. Experimental Center, Jilin Medical College, Jilin 132013, China
  • Received:2015-06-03 Published:2016-01-26

摘要:

目的: 研究黄芪甲苷对链脲佐菌素(STZ)所致糖尿病肾病(DN)大鼠的氧自由基代谢及转化生长因子β1(TGF-β1)mRNA表达水平的影响,并探讨其相关作用机制。 方法: 60只Wistar大鼠分为对照组、模型组、厄贝沙坦(14.37 mg·kg-1)组和低剂量(0.75 mg·kg-1)、中剂量(1.50 mg·kg-1)及高剂量(3.00 mg·kg-1)黄芪甲苷组,每组10只。除对照组外,其余各组大鼠腹腔注射 60 mg·kg-1STZ,每日灌胃相应药物并用高脂饲料喂养。8周后,检测各组大鼠血清中肌酐(Scr)、尿素氮(BUN)、空腹血糖(FBG)水平和24h尿蛋白量;检测各组大鼠肾组织中超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)活性及丙二醛(MDA)水平;RT-PCR法检测肾组织中过氧化氢酶(CAT)和TGF-β1 mRNA 表达水平。 结果: 与模型组比较,中、高剂量黄芪甲苷组DN大鼠肾功能明显改善,各剂量黄芪甲苷组大鼠血清Scr水平降低(P<0.05或 P<0.01),中、高剂量黄芪甲苷组大鼠血清中BUN、FBG水平和24h尿蛋白量降低 (P<0.05或P<0.01)。与模型组比较,中、高剂量黄芪甲苷组大鼠肾组织中MDA水平降低、SOD活性升高(P<0.05或P<0.01),TGF-β1mRNA表达水平降低(P<0.05);各剂量黄芪甲苷组大鼠肾组织中GSH-Px活性均升高(P<0.05或P<0.01), CATmRNA表达水平无明显变化(P>0.05)。 结论: 黄芪甲苷可以改善DN大鼠的肾功能,其作用机制可能与改善肾内氧自由基的氧化损伤及降低肾组织TGF-β1mRNA表达有关。

关键词: 黄芪甲苷, 糖尿病肾病, 氧化应激, 氧自由基, 转化生长因子&beta, 1

Abstract:

Objective: To study the effect of astragaloside on the oxygen radical metabolism and (DN)the expression of transforming grow th factor β1(TGF-β1)mRNA in the rats with STZ-induced diabetic nephropathy(DN), and to clarify its related mechanism. Methods: 60 Wistar rats were divided into control group,model group,irbesartan group,low dose (0.75 mg·kg·d-1)of astragaloside group,middle dose (1.50 mg·kg·d-1)of astragaloside group and high dose (3.00 mg·kg·d-1)of astragaloside group(n=10).Except control group,the rats in other groups were intraperitoneally injected with 60 mg·kg·d-1 STZ to induce DN models.8 weeks later,the levels of serum creatinine(Scr),blood urea nitrogen(BUN),fasting blood glucose,and 24 h urinary protein of the rats in various groups were detected.The SOD and GSH-Px activities and MDA levels in kidney tissue of the rats in various groups were measured;the expression levels of CAT and TGF-β1 mRNA in kidney tissue were determined by RT-PCT. Results: Compared with model group,the kidney function of the DN rats in middle and high doses of astragaloside groups was improved;the serum Scr levels of the rats in astragloside groups were decreased (P<0.05 or P<0.01),and the levels of serum BUN and PBG and 24 h urinary protein of the rats in middle and high doses of astragaloside groups were decreased(P<0.05 or P<0.01).Compared with model group,the MDA levels in kidney tissue of the rats in middle and high doses of astragaloside groups were decreased and the SOD activites were increased(P<0.05 or P<0.01); the expression levels of TGF-β1 mRNA were decreased(P<0.05); the GSH activities in kidney tissue of the rats in various doses of astragaloside groups were increased P<0.05 or P<0.01); but the expression levels of CAT mRNA had no changes(P>0.05). Conclusion: Astragaloside can improve the kidney function of DN rats,its mechanism may be related to the improvement of oxygen radical damage and reduction of TGF-β1 mRNA expression.

Key words: astragaloside, diabetic nephropathy, oxidative stress, reactive oxygen species, transforming growth factor β1

中图分类号: 

  • R285.5